Pinnacle Medicines Raises $89M Series B
TL;DR AI
2 min readKey summary
Pinnacle Medicines closed an oversubscribed $89 million Series B financing.
The round was co-led by LAV and Foresite Capital with participation from several venture firms including OrbiMed.
The company develops oral peptide therapeutics using AI and physics-based molecular simulation and is advancing programs for immunology and cardiometabolic targets.